secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069811
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma Q1 net loss $12.9M; setrusumab Phase 3 Orbit on track for mid-year readout
--------------------------------------------------------------------------------

- Net loss widened to $12.9M (Q1 2024: $9.0M) on operating loss of $11.2M.
- Cash and equivalents $62.5M at March 31, 2025, down from $69.8M at year-end; runway into 2027.
- R&D expenses $3.9M, flat YoY; setrusumab costs increased $1.3M offset by alvelestat decrease.
- Phase 3 Orbit study of setrusumab in OI on track for second interim mid-2025 or final Q4 2025.
- Alvelestat granted EU orphan designation for alpha-1 antitrypsin deficiency lung disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025069811/0000950170-25-069811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025069811/mreo-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer